Men diagnosed at this hospital trust can access the following services:

• Diagnostic Facilities:
• Multiparametric MRI
• Transperineal biopsy under local anaesthetic
• Transperineal biopsy under general anaesthetic
• Transrectal ultrasound (TRUS) biopsy
• Choline PET
• PSMA (prostate-specific membrane antigen) PET scan
• Isotope bone scan
• One-stop diagnostic clinic

• Treatment Facilities:
• Chemotherapy
• Joint specialist MDT clinic

• Support Service Facilities:
• Clinical Nurse Specialist (CNS) in all clinics
• Advanced PCa CNS
• Urology CNS
• Sexual function services
• Specialist continence services
• Genetic counselling

For Wales, this data completeness relates to patients diagnosed between April 2022 and March 2023.
For England, this data completeness relates to patients diagnosed in 2021. This is the data completeness of the National Cancer Registration Dataset (NCRD). For data completeness of the Rapid Cancer Registration Dataset (RCRD), please refer to the NPCA quarterly reports.

	Diagnosing Trust	Specialist MDT
No. of Cancer Registry records	241	241
Performance Status recorded	72%	72%
PSA completed	6%	6%
Gleason Score completed	94%	94%
TNM completed	54%	54%

For Wales, these results relate to patients diagnosed between April 2022 and March 2023.
For England, these results relate to patients diagnosed between January and December 2021.

	Specialist MDT	National
No. of men with disease status determined	188	39897
Percentage of men diagnosed with metastatic disease	7%	17%

For Wales, these results relate to patients diagnosed between April 2022 and March 2023.
For England, these results relate to patients diagnosed between January and December 2021.

	Specialist MDT	National
No. of men diagnosed with low-risk localised disease	41	4684
Percentage of men with low-risk localised disease receiving radical treatment	14%	8%
No. of men diagnosed with locally advanced disease	78	15410
Percentage of men diagnosed with locally advanced disease receiving radical treatment	71%	68%